Sex and Age Differences in the Pharmacokinetics of Alosetron

Overview

Journal Br J Clin Pharmacol

Specialty Pharmacology

Date 2002 Mar 5

PMID 11874386

Citations 16

Authors

K M Koch

J L Palmer

N Noordin

J J TOMLINSON

C Baidoo

Affiliations

Soon will be listed here.

Abstract

Aims: To determine the effects of sex and age on the pharmacokinetics of alosetron.

Methods: Single oral and intravenous 2 mg doses of alosetron were administered on separate occasions to 48 healthy, young and elderly, males and females. Serum was sampled for 12 h post-dose to measure alosetron concentrations.

Results: Serum concentrations of alosetron were higher in females than in males, resulting from a sex difference in clearance by metabolism. Mean clearance values were 504 vs 677 ml min(-1) in young females vs males (mean ratio 0.75), and 461 vs 670 ml min(-1) in elderly females vs males (mean ratio 0.69). The sex difference in alosetron pharmacokinetics achieved statistical significance in the elderly, but not in the young. Irrespective of sex, alosetron clearance was increased by smoking. Serum concentrations tended to be higher in the elderly, although the effect of age was generally not significant. Volume of distribution was smaller in females (approximately 63 l) compared with males (approximately 84 l), regardless of age or the sex difference in body weight.

Conclusions: A significant difference in clearance by metabolism of alosetron between the sexes, and possibly between the young and elderly was observed.

Citing Articles

Genetic hypogonadal (Gnrh1) mouse model uncovers influence of reproductive axis on maturation of the gut microbiome during puberty.

Sisk-Hackworth L, Akhavan S, Krutkin D, Kelley S, Thackray V bioRxiv. 2024; .

PMID: 39005422 PMC: 11245025. DOI: 10.1101/2024.07.01.601610.

Harnessing Clinical Trial and Real-World Data Towards an Understanding of Sex Effects on Drug Pharmacokinetics, Pharmacodynamics and Efficacy.

Oi Yan Chan J, Moullet M, Williamson B, Arends R, Pilla Reddy V Front Pharmacol. 2022; 13:874606.

PMID: 35734405 PMC: 9207260. DOI: 10.3389/fphar.2022.874606.

Sex-Bias in Irritable Bowel Syndrome: Linking Steroids to the Gut-Brain Axis.

So S, Savidge T Front Endocrinol (Lausanne). 2021; 12:684096.

PMID: 34093447 PMC: 8170482. DOI: 10.3389/fendo.2021.684096.

Population pharmacokinetics of ramosetron.

Lee S, Cho S, Yoo K, Jeong S J Pharmacokinet Pharmacodyn. 2015; 43(1):73-83.

PMID: 26558626 DOI: 10.1007/s10928-015-9455-8.

The clinical potential of ramosetron in the treatment of irritable bowel syndrome with diarrhea (IBS-D).

Min Y, Rhee P Therap Adv Gastroenterol. 2015; 8(3):136-42.

PMID: 25949526 PMC: 4416292. DOI: 10.1177/1756283X15572580.

References

Camilleri M, Northcutt A, Kong S, Dukes G, McSorley D, Mangel A . Efficacy and safety of alosetron in women with irritable bowel syndrome: a randomised, placebo-controlled trial. Lancet. 2000; 355(9209):1035-40. DOI: 10.1016/S0140-6736(00)02033-X. View

Callaghan J, Bergstrom R, Ptak L, Beasley C . Olanzapine. Pharmacokinetic and pharmacodynamic profile. Clin Pharmacokinet. 1999; 37(3):177-93. DOI: 10.2165/00003088-199937030-00001. View

Watkins P, Murray S, Winkelman L, Heuman D, Wrighton S, Guzelian P . Erythromycin breath test as an assay of glucocorticoid-inducible liver cytochromes P-450. Studies in rats and patients. J Clin Invest. 1989; 83(2):688-97. PMC: 303730. DOI: 10.1172/JCI113933. View

Sandler R . Epidemiology of irritable bowel syndrome in the United States. Gastroenterology. 1990; 99(2):409-15. DOI: 10.1016/0016-5085(90)91023-y. View

Haring C, Fleischhacker W, Schett P, Humpel C, Barnas C, Saria A . Influence of patient-related variables on clozapine plasma levels. Am J Psychiatry. 1990; 147(11):1471-5. DOI: 10.1176/ajp.147.11.1471. View

Ereshefsky L, Saklad S, Watanabe M, Davis C, Jann M . Thiothixene pharmacokinetic interactions: a study of hepatic enzyme inducers, clearance inhibitors, and demographic variables. J Clin Psychopharmacol. 1991; 11(5):296-301. View

Warrington S . Clinical implications of the pharmacology of sertraline. Int Clin Psychopharmacol. 1991; 6 Suppl 2:11-21. DOI: 10.1097/00004850-199112002-00004. View

Hunt C, Westerkam W, Stave G . Effect of age and gender on the activity of human hepatic CYP3A. Biochem Pharmacol. 1992; 44(2):275-83. DOI: 10.1016/0006-2952(92)90010-g. View

Relling M, Lin J, Ayers G, Evans W . Racial and gender differences in N-acetyltransferase, xanthine oxidase, and CYP1A2 activities. Clin Pharmacol Ther. 1992; 52(6):643-58. DOI: 10.1038/clpt.1992.203. View

10.

Ford J, Truman C, Wilcock G, Roberts C . Serum concentrations of tacrine hydrochloride predict its adverse effects in Alzheimer's disease. Clin Pharmacol Ther. 1993; 53(6):691-5. DOI: 10.1038/clpt.1993.91. View

11.

Butler M, Lang N, Young J, Caporaso N, Vineis P, Hayes R . Determination of CYP1A2 and NAT2 phenotypes in human populations by analysis of caffeine urinary metabolites. Pharmacogenetics. 1992; 2(3):116-27. DOI: 10.1097/00008571-199206000-00003. View

12.

Harris R, Benet L, Schwartz J . Gender effects in pharmacokinetics and pharmacodynamics. Drugs. 1995; 50(2):222-39. DOI: 10.2165/00003495-199550020-00003. View

13.

Lloyd T, Gupta S, Gooding A, Alianti J . Determination of alosetron in human plasma or serum by high-performance liquid chromatography with robotic sample preparation. J Chromatogr B Biomed Appl. 1996; 678(2):261-7. DOI: 10.1016/0378-4347(95)00491-2. View

14.

Barbhaiya R, Buch A, Greene D . A study of the effect of age and gender on the pharmacokinetics of nefazodone after single and multiple doses. J Clin Psychopharmacol. 1996; 16(1):19-25. DOI: 10.1097/00004714-199602000-00004. View

15.

Gorski J, Jones D, Hamman M, OMara Jr E, Hall S . The contribution of intestinal and hepatic CYP3A to the interaction between midazolam and clarithromycin. Clin Pharmacol Ther. 1998; 64(2):133-43. DOI: 10.1016/S0009-9236(98)90146-1. View

16.

Camilleri M, Mayer E, Drossman D, Heath A, Dukes G, McSorley D . Improvement in pain and bowel function in female irritable bowel patients with alosetron, a 5-HT3 receptor antagonist. Aliment Pharmacol Ther. 1999; 13(9):1149-59. DOI: 10.1046/j.1365-2036.1999.00610.x. View

17.

Richardson C, Blocka K, Ross S, Verbeeck R . Effects of age and sex on piroxicam disposition. Clin Pharmacol Ther. 1985; 37(1):13-8. DOI: 10.1038/clpt.1985.4. View